[graphic-home]
Welcome to Syenza
Innovative healthcare technologies improve health, when accessible!
A future of vibrant health awaits, but access barriers are complex and seem insurmountable. Syenza advances access with our HEOR, Global Market Access, and Dynamic Intelligence scientific services for Pharmaceutical, Medtech, and Biotech businesses. Simply put, value science is how we accelerate access to innovations that improve health.
Syenza News
- FDA Rare Disease Framework Initiative Would Tailor Review to Small Populations October 15, 2026What steps is the FDA taking to accelerate rare disease treatments? The FDA’s new Rare Disease Framework Initiative aims to streamline regulatory pathways, enhance collaboration with sponsors, and improve patient access to innovative therapies. Explore how this could reshape drug development for underserved patient populations. #SyenzaNews #regulatoryaffairs #drugdevelopment #innovation #healthcarepolicyJoão L. Carapinha
- Semaglutide for Opioid Use Disorder: $13.3M Trial Planned in Allegheny County October 15, 2026Researchers and Allegheny County plan a $13.3 million trial of weekly semaglutide to reduce opioid and alcohol use and justice involvement.João L. Carapinha
- AI guidance in clinical development: what industry is asking for October 15, 2026Regulators at the HMA-EMA AI group on 5 October 2026 outlined AI guidance in clinical development, with a concept paper and public consultation to follow.João L. Carapinha